Difference between revisions of "Team:ASIJ Tokyo"
19andersonn (Talk | contribs) |
|||
| Line 6: | Line 6: | ||
margin-right: 10px; | margin-right: 10px; | ||
} | } | ||
| − | |||
#everything { | #everything { | ||
background-color: #fddea5 | background-color: #fddea5 | ||
} | } | ||
| − | |||
#liver { | #liver { | ||
position: absolute; | position: absolute; | ||
| Line 17: | Line 15: | ||
width: 500px; | width: 500px; | ||
} | } | ||
| − | |||
#title p{ | #title p{ | ||
font-size: 85px; | font-size: 85px; | ||
| Line 29: | Line 26: | ||
letter-spacing: 15px; | letter-spacing: 15px; | ||
} | } | ||
| − | |||
#red { | #red { | ||
color: #c53d43; | color: #c53d43; | ||
} | } | ||
| − | |||
div.container | div.container | ||
{ | { | ||
| Line 44: | Line 39: | ||
text-align: center; | text-align: center; | ||
} | } | ||
| − | |||
div.container a | div.container a | ||
{ | { | ||
| Line 56: | Line 50: | ||
cursor: pointer; | cursor: pointer; | ||
} | } | ||
| − | |||
div.topBotomBordersOut a:before, div.topBotomBordersOut a:after | div.topBotomBordersOut a:before, div.topBotomBordersOut a:after | ||
{ | { | ||
| Line 68: | Line 61: | ||
transition: all 0.3s; | transition: all 0.3s; | ||
} | } | ||
| − | |||
div.topBotomBordersOut a:before | div.topBotomBordersOut a:before | ||
{ | { | ||
| Line 74: | Line 66: | ||
transform: translateY(10px); | transform: translateY(10px); | ||
} | } | ||
| − | |||
div.topBotomBordersOut a:after | div.topBotomBordersOut a:after | ||
{ | { | ||
| Line 80: | Line 71: | ||
transform: translateY(-10px); | transform: translateY(-10px); | ||
} | } | ||
| − | |||
div.topBotomBordersOut a:hover:before, div.topBotomBordersOut a:hover:after | div.topBotomBordersOut a:hover:before, div.topBotomBordersOut a:hover:after | ||
{ | { | ||
| Line 86: | Line 76: | ||
transform: translateY(0px); | transform: translateY(0px); | ||
} | } | ||
| − | |||
#abstract { | #abstract { | ||
| − | + | position: relative; | |
top: 500px; | top: 500px; | ||
} | } | ||
| − | |||
</style> | </style> | ||
| Line 101: | Line 89: | ||
<body> | <body> | ||
| − | |||
<div id="everything"> | <div id="everything"> | ||
<div class="container topBotomBordersOut"> | <div class="container topBotomBordersOut"> | ||
| Line 112: | Line 99: | ||
</div> | </div> | ||
| − | <div id="title"><p> A1-AT <br> DE<span id="red">LIVER</span>Y </p></div> | + | <div id="title"><p>A1-AT<br>DE<span id="red">LIVER</span>Y </p></div> |
| − | + | <img src="https://static.igem.org/mediawiki/2018/e/ed/T--ASIJ_Tokyo--liverlogocut.png" id="liver"></img> | |
| − | <img src="https://static.igem.org/mediawiki/2018/e/ed/T--ASIJ_Tokyo--liverlogocut.png" id="liver"> | + | <div id="abstract"> |
| − | + | <h1> A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h1> | |
| − | + | <h3> ABSTRACT </h3> | |
| − | <div id="abstract"> | + | <p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK. </p> |
| − | <h1> A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency </h1> | + | </div> |
| − | <h3> ABSTRACT </h3> | + | |
| − | <p> Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK. </p> | + | |
| − | </div> | + | |
| − | + | ||
| − | + | ||
</div> | </div> | ||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 04:22, 29 June 2018
A1-AT
DELIVERY
A1AT deLIVERy - Using Stem Cell and CRISPR Technology to Combat Alpha-1 Antitrypsin Deficiency
ABSTRACT
Alpha-1 Antitrypsin deficiency is a common genetic disorder -- the defective gene for which is carried by 1 in 25 people -- which arises from a single base pair mutation in the SERPINA1 gene, resulting in the production of a form of antitrypsin prone to polymerization. The mutated antitrypsin then builds up in liver cells and is unable to inhibit proteases in the lungs, leading to damage in both. Using CRISPR-Cas9 technology, we aimed to fix the error in SERPINA1 so that proper antitrypsin can be produced. We will show proof of concept in E. Coli cells using osmy secretion tags and GFP as a reporter. We hope to design a liver organ bud using IPS cell technology to deliver function A1AT through collaboration with Dr. Kagimoto of Healios Japan KK.